亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

医学 内科学 曲妥珠单抗 临床终点 胃肠病学 免疫组织化学 肿瘤科 癌症 外科 乳腺癌 临床试验
作者
Funda Meric‐Bernstam,Vicky Makker,Ana Oaknin,Do‐Youn Oh,Susana N. Banerjee,Antonio González-Martín,Kyung Hae Jung,Iwona A. Lugowska,Luís Manso,Aránzazu Manzano,Bohuslav Melichar,Salvatore Siena,Daniil Stroyakovskiy,Anitra Fielding,Yan Ma,Soham D. Puvvada,Norah J. Shire,Jung‐Yun Lee
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (1): 47-58 被引量:1198
标识
DOI:10.1200/jco.23.02005
摘要

PURPOSE: Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)-directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers and HER2-mutant non-small-cell lung cancer. Treatments are limited for other HER2-expressing solid tumors. METHODS: This open-label phase II study evaluated T-DXd (5.4 mg/kg once every 3 weeks) for HER2-expressing (immunohistochemistry [IHC] 3+/2+ by local or central testing) locally advanced or metastatic disease after ≥1 systemic treatment or without alternative treatments. The primary end point was investigator-assessed confirmed objective response rate (ORR). Secondary end points included safety, duration of response, progression-free survival (PFS), and overall survival (OS). RESULTS: At primary analysis, 267 patients received treatment across seven tumor cohorts: endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and other. The median follow-up was 12.75 months. In all patients, the ORR was 37.1% (n = 99; [95% CI, 31.3 to 43.2]), with responses in all cohorts; the median DOR was 11.3 months (95% CI, 9.6 to 17.8); the median PFS was 6.9 months (95% CI, 5.6 to 8.0); and the median OS was 13.4 months (95% CI, 11.9 to 15.5). In patients with central HER2 IHC 3+ expression (n = 75), the ORR was 61.3% (95% CI, 49.4 to 72.4), the median DOR was 22.1 months (95% CI, 9.6 to not reached), the median PFS was 11.9 months (95% CI, 8.2 to 13.0), and the median OS was 21.1 months (95% CI, 15.3 to 29.6). Grade ≥3 drug-related adverse events were observed in 40.8% of patients; 10.5% experienced adjudicated drug-related interstitial lung disease (ILD), with three deaths. CONCLUSION: Our study demonstrates durable clinical benefit, meaningful survival outcomes, and safety consistent with the known profile (including ILD) in pretreated patients with HER2-expressing tumors receiving T-DXd. Greatest benefit was observed for the IHC 3+ population. These data support the potential role of T-DXd as a tumor-agnostic therapy for patients with HER2-expressing solid tumors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
852的应助被liuqiwei采纳,获得200
刚刚
6秒前
彩色白竹完成签到,获得积分10
7秒前
7秒前
8秒前
bwx发布了新的文献求助200
8秒前
19秒前
傻傻的含莲完成签到,获得积分10
20秒前
20秒前
24秒前
丘比特的应助被执着念烟采纳,获得10
25秒前
25秒前
25秒前
27秒前
28秒前
28秒前
29秒前
29秒前
30秒前
32秒前
33秒前
33秒前
33秒前
33秒前
34秒前
35秒前
35秒前
36秒前
38秒前
38秒前
40秒前
41秒前
jjj完成签到 ,获得积分10
42秒前
42秒前
42秒前
纯情的阁发布了新的文献求助10
43秒前
43秒前
43秒前
纯情的阁发布了新的文献求助10
43秒前
纯情的阁发布了新的文献求助10
43秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158848
求助须知:如何正确求助?哪些是违规求助? 9554492
关于积分的说明 21719333
捐赠科研通 7748419
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2552006
邀请新用户注册赠送积分活动 2471370